In the Media


Active Motif team Dr. Rwik Sen, Zachary Verlander, and Alisa Cummings publish an insightful review “Advances in understanding epigenetic impacts on dendritic cell regulation and function.” Clinical and Translational Discovery, June 21, 2022.

Active Motif scientist Dr. Benjamin Delatte publishes work on a novel method for analysis of DNA Methylation: “Anchor-based bisulfite sequencing determines genome-wide DNA methylation.” Communications Biology, June 16, 2022.

Active Motif's Recombinant Human SARS-CoV-2 antibodies published in the journal Science as part of a global consortium study to define variant-resistant epitopes

Active Motif scientist, Dr. Rwik Sen, publishes work on cardiac development & regeneration using Zebrafish as a model for high-throughput research.

Press Releases

Active Motif Incorporated Licenses Targeted Transposition Technology to Diagenode S.A.

Active Motif and EpiCypher Execute Cross-Licensing Agreement and End Ongoing Litigation Involving Targeted Transposition/CUT&Tag Technology for Epigenomics

Active Motif Incorporated Announces the Acquisition of Amaryllis Nucleics and their proprietary RNASeq workflow

Proteintech Expands Collaboration With Epigenetics Company Active Motif

Active Motif Partners with Arima Genomics to Launch End-to-End Hi-C Service

Active Motif Announces New Report Describing Advancements in Generation and Characterization of Their Recombinant Human COVID-19 Antibodies with Qualities that Make Them Ideal for Use in Diagnostics and Therapeutics

Licensing of patient-derived COVID-19 neutralizing antibodies to Hisun Pharma for co-development and clinical use.

Active Motif launches a portfolio of recombinant COVID-19 antibodies; the first full human antibodies derived from patients infected with the 2019 Coronavirus, now available for research and commercial use.

Active Motif clones, sequences and expresses the first full human antibody derived from patients infected with the 2019 Coronavirus COVID-19.

Active Motif Partners With Benchsci to Increase Discoverability of Epigenetics-related Products

OnRamp's ROSALIND and Active Motif offer an improved ChIP-Seq data analysis experience for researchers with state-of-the-art dynamics track plots and advanced collaboration capabilities

VolitionRx's First Research Use Only Product Is "On-The-Shelf" Today

VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits

University of Giessen enhances their genome analysis capability with the addition of TimeLogic’s FPGA-based Biocomputing platform

Graz University of Technology enhances their genome analysis capability with the addition of TimeLogic’s FPGA-based Biocomputing platform

Active Motif and Swift Biosciences partner to develop advancements in epigenetics

Forge Therapeutics and Active Motif to Collaborate on Epigenetic Research and Drug Discovery

ChemPartner and Active Motif Form an Epigenetic Biochemical Technology Alliance

Active Motif Acquires SwitchGear Genomics, Inc. Further Expanding Gene Regulation Product Offerings

Active Motif Acquires Genpathway, Inc. Further Expanding Epigenetics Product Offerings

Active Motif Awarded SBIR Grant to Develop Chromatin IP of Clinical Samples

Active Motif Licenses Methylated-CpG Island Recovery Assay (MIRA) from City of Hope